Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8281689 | 1.00 | ACHE (0.50) | ACHEDRD2DRD1CTSDBACE1 | |
| Hydrochloric Acid SCHEMBL3171185 | 0.98 | ACHE (0.49) | ACHEDRD2DRD1CTSDBACE1 | |
| SCHEMBL21065657 | 0.90 | ACHE (0.48) | ACHEDRD2DRD1HTR1AHTR2A | |
| SCHEMBL18616366 | 0.87 | OPRD1 (0.47) | ACHEOPRD1 | |
| SCHEMBL16543141 | 0.87 | OPRD1 (0.47) | ACHEOPRD1 | |
| SCHEMBL16543139 | 0.87 | OPRD1 (0.47) | ACHEOPRD1 | |
| SCHEMBL8278065 | 0.83 | ACHE (0.45) | ACHEDRD2CTSDBACE1OPRD1 | |
| SCHEMBL5713887 | 0.83 | ACHE (0.45) | ACHEDRD2CTSDBACE1OPRD1 | |
| SCHEMBL5713886 | 0.81 | DRD2 (0.41) | DRD2DRD1CTSDBACE1HTR1A | |
| SCHEMBL3170918 | 0.80 | DRD2 (0.43) | ACHEDRD2DRD1CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | BACE2, BACE1, APP | ACHE 45/4885DRD2 3852/4885DRD1 3686/4885 |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | ACHE 965/4885DRD2 4885/4885DRD1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.